TGFβ-1 mRNA Expression and Proliferation of Human Osteoblastic Cells in Nonosteoporotic and Osteoporotic Women under Influence of TGFβ-1 and IGF-I

Abstract

Currently, primary osteoporosis is the most frequent metabolic disease in women after menopause [1]. The resulting loss of bone mass is accompanied by an increased risk of skeletal fragility. One reason for the development of osteoporosis might be an impaired function of mature osteoblasts. To evaluate the involvement of specific growth factors in bone remodeling, cell cultures of osteoblastic cells derived from nonosteoporotic and osteoporotic postmenopausal women were established. The influences of TGF beta-1 and IGF-I on proliferation and mRNA expression of TGF beta-1 were investigated by [3H]-thymidine incorporation and competitive RT-PCR. We found IGF-I to have no significant effect on proliferation in cells of osteoporotic and nonosteoporotic patients. In contrast, differences were found in TGF beta-1 mRNA expression after application of IGF-I. Application of TGF beta-1 enhanced its own mRNA expression in both groups in a similar manner. Whereas the proliferation of cells of nonosteoporotic patients was inhibited by (10(-10) M) TGF beta-1, this treatment led to an increased proliferation of cells of osteoporotic patients.

Biocompatibility and osseointegration in osteoporotic bone

“…19,20 Varying results have been obtained by different authors when comparing healthy osteoblasts with cells from osteoporotic patients. Even if the phenotype characterisation did not show variations between normal and osteopenic-bone-derived cells, differences in the rate of proliferation 21,22 or in the response to cytokines, hormones or mechanical stimuli 18,23,24 have been observed.…”

Isolation and characterization of osteoblast cultures from normal and osteopenic sheep for biomaterials evaluation

“…Regarding osteoporosis, which is a health problem of clinical relevance, there are some in vitro studies in which the differences in activation and proliferation rate of cell cultures derived from osteoporotic patients were studied in comparison with normal bone-derived cells. [26][27][28][29] Even if awareness that bone rarefaction may create a gap between bone, and material implantation has already been achieved in in vivo studies, [30][31][32][33] our group was the first to focus the attention on the possibility of using osteopenic bonederived cells also for the evaluation of orthopedic biomaterials, starting from the assumption that devices are often implanted in patients with bone rarefaction due to primary or secondary osteoporosis. It is our opinion that the in vitro evaluation of this clinical situation could improve data on biocompatibility and osteointegration of biomaterials in the initial phases of a research, thus reducing the number of animals required for subsequent in vivo investigations.…”

Human Osteopenic Bone‐Derived Osteoblasts: Essential Amino Acids Treatment Effects

“…The possibility of culturing primary osteoblasts from the human skeleton has made it possible to conduct a great amount of research on osteoblasts cultured from osteoporotic patients and elucidate the different dysfunction patterns and responsiveness of cells to therapies (Katzburg et al, 1999;Sasse et al, 1998). Some of these studies have reported that no or little difference exists between healthy and osteoporotic bone-derived osteoblasts in terms of proliferation, synthetic activity and morphology (Lomri and Marie, 1990;Walsh et al, 2000).…”